Related references
Note: Only part of the references are listed.Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?
Atocha Romero et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2012)
HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy
George Fountzilas et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
Multifactorial Approach to Predicting Resistance to Anthracyclines
Christine Desmedt et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Alteration of Topoisomerase II-Alpha Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based Chemotherapy
Michael F. Press et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer
Gottfried E. Konecny et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Are HER2 and TOP2A Useful As Prognostic or Predictive Biomarkers for Anthracycline-Based Adjuvant Chemotherapy for Breast Cancer?
Kathleen I. Pritchard
JOURNAL OF CLINICAL ONCOLOGY (2009)
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer:: A pooled analysis of randomized trials
Alessandra Gennari et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
HER2/neu in systemic therapy for women with breast cancer:: a systematic review
Bindi Dhesy-Thind et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Topoisomerase IIα gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer:: Scandinavian Breast Group Trial 9401
Minna Tanner et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
HER2 and responsiveness of breast cancer to adjuvant chemotherapy
KI Pritchard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:: Danish Breast Cancer Cooperative Group
AS Knoop et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients
L Del Mastro et al.
BRITISH JOURNAL OF CANCER (2005)
Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer:: a prospective randomised study
M Colozza et al.
EUROPEAN JOURNAL OF CANCER (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer
TAH Jarvinen et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
